



Korean Intellectual Property Tribunal Overturns Korean Patent Office's Refusal of Asha's Patent Application - Notice of Allowance Issued Subsequently

The patent application is related to Asha's LipiLife product line, which provides tailored dosages of lipids; the patent covers additional product applications.

Palo Alto, CA – July 25, 2019 – Asha Nutrition Sciences, Inc. (Asha), announced today that the Korean Intellectual Property Tribunal, Seventh Department (KIPT) has reversed the Korean Intellectual Property Office's (KIPO) Decision rejecting Asha's Korean Patent Application No. 2010-7026029. Reversing KIPO's position KIPT ruled that there is no lack of clarity, added matter, and lack of enablement in the claims pending in the application in its Judgement rendered on June 27, 2019 in Trial No. 2017 won 5015.

The Notice of Allowance on all 40 claims was subsequently issued by KIPO on July 12, 2019.

The broadest claim 1 reads as follows:

“A lipid-containing formulation, comprising a mixture of lipids from different sources, wherein the formulation comprises a dosage of omega-6 and omega-3 fatty acids at an omega-6 to omega-3 ratio of at least 4:1 w/w, w/v, or v/v, wherein omega-3 fatty acids are 0.1-20% by weight of total lipid.”

This family of patents and applications originates from Asha's International Patent Application Number PCT2009/041114. The patent applications are drawn to controlled dosages of omega-6 and omega-3 and other lipids, wherein omega-6 is greater than omega-3 and/or total lipids in proportions that are opposite of teachings in the prior art. ***This technology and disclosure were necessitated by the fact that at the priority date of the application there were overwhelming opposite teachings in the art teaching extremely low intake of omega-6 fatty acids and suppression of its activity compromising public health at a large scale.*** However, holding the scope of the application against Asha, US Patent and Trademark Office (USPTO) and the European Patent Office (EPO) excised certain limitations from the claims and issued fabricated clarity, added matter, enablement, and other rejections. Asha has contested the US and European cases of which US Application number 13/332,251 has been granted as US Patent 10,292,958. Asha has petitioned improper rejections on other US and European cases to the Supreme Court of the United States, the Congress of the United States, and the Administrative Council of the European Patent Organizations, and reported the same to Heads of States in US, Europe, and Japan.

Ms. Urvashi Bhagat, Asha CEO said that “We applaud the Korean judges for rendering justice though late. Various patent offices have obstructed this important innovation contrary to the charge of the patent offices at great public health cost. This is creating a humanitarian crisis.” She added, “The purpose of the patent system is to solve significant problems for the benefit of the humanity. It is not to issue piecemeal patents that create

more chaos. We intend to keep building on this patent portfolio to comprehensively solve the lipid problem that has continued to plague humanity for over 100 years.”

Asha is committed to development of industry leading lipid solutions with potential to vastly protect and enhance public health. WHO estimates about 2 billion people worldwide suffer from chronic and infectious diseases. Studies show that lipid imbalance is associated with a variety of chronic diseases including diabetes, heart disease, strokes, arthritis, asthma, attention deficit hyperactivity disorder, neural disease, depression, and cancer, and compromised immunity. Approximately 80 percent of the costs of healthcare are due to chronic conditions, costing nearly 3 trillion dollars annually in US. Further, lipids are unpredictable in nature, and less than 1% of the public understands lipids. Thus, Asha’s technology is a solution to a critical unmet public health need.

Asha’s flagship product is LipiLife, made up of fats, fat-soluble vitamins and sterols that are vital for health and well-being and vary by demographics. Currently, LipiLife is available in vegetarian and non-vegetarian formulas for women and men individually.

Ms. Bhagat added, “We invite collaboration from corporate partners for marketing and manufacturing of our products and/or licensing of our intellectual property for infant foods, pet foods, and/or therapeutic applications for medical indications so that this lipid problem can be eradicated for good.”

"Lipids are critical for health," explains Dr. Undurti N. Das, Chief Medical Officer of Asha Nutrition Sciences. "Every cell in the body is enveloped in lipids, and the cell cannot function without the right balance of lipids. Health benefits of balanced lipids are across multiple indications because lipids affect a broad range of physiological functions. Lipid requirements vary by members of a family. Therefore, lipids should be pre-formulated and tailored for the public."

Asha aims to create a brighter future for world health by preventing current trends from continuing. LipiLife radically shifts the way people consider what it means to consume healthy fats and how chronic health issues are preventable and even reversible with the right lipid formula and methods.

About Asha Nutrition Sciences, Inc.

Asha Nutrition Sciences is a private wellness company offering tailored nutrition with balanced lipids, antioxidants, and phytochemicals with LipiLife and other product lines. Lipids are the basis of life, as crucial cell membranes components, as gene regulators, and as precursors of hormones and other bioactive compounds. Lipids affect a broad range of physiological functions and health. Antioxidants, phytochemicals, vitamins, minerals, proteins, carbohydrates, hormones, and temperature materially alter lipid metabolism. Therefore, the precise requirements of lipids change by diet type, gender, stage of life, climactic temperature, and other factors. For more information, visit <http://asha-nutrition.com>.

Forward-Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements based on current expectations subject to uncertainties. Asha undertakes no obligation to publicly update any forward-looking statements.

Asha Nutrition Sciences, Inc.
media@asha-nutrition.com